The N-terminal pro-brain natriuretic peptide (NT-proBNP) assay with the Stratus®CS analyzer;Évaluation des performances analytiques du dosage du NT-proBNP sur analyseur semi-automatisé Stratus®CS

Annales de Biologie Clinique

Volumn 65, Issue 1, 2007, Pages 77-82

  Chenevier Gobeaux, C ^a   Guillot, D ^a   Ursulet, J ^b   Paul, J L ^b   Ekindjian, O G ^a   Desmoulins, D ^a   Benoit, M O ^b  

^a Institut Cochin   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Analytical performance; Dimension HM; Immunoenzymatic assay; N terminal pro brain natriuretic peptide; Stratus CS

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); UNCLASSIFIED DRUG;

ARTICLE; BLOOD; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; ENZYME IMMUNOASSAY; HUMAN; METHODOLOGY; REPRODUCIBILITY; STATISTICAL MODEL; VALIDATION STUDY;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOENZYME TECHNIQUES; LINEAR MODELS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS;

EID: 34147106494     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2007.0028     Document Type: Article

References (12)

1. Hall C. NT-proBNP: the mechanism behind the marker. J Card Fail 2005 ; 11 : S81-S83.
2. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest 1999 ; 59 : 132-42.
3. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides : a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003 ; 4 : 72-80.
4. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care : a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004 ; 6 : 295-300.
5. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003 ; 42 : 728-35.
6. Januzzi Jr JL, Camargo CA, Anwaruddin S, et al. The N-terminal ProBNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005 ; 95 : 948-54.
7. Benoit MO, Dautezac F, Taccoen M, Paul JL. Evaluation of the analytical performance characteristics of NT-proBNP immunoassay on dimension RxL-HM (Dade Behring). Ann Biol Clin (Paris) 2005 ; 63 : 411-6.
8. Vassault A. Procédure de validation de techniques. Spectra Biologie 1997 ; 16 : 43-50.
9. Vassault A, Baud M, Castaignier M, et al. Recommandations pour la comparaison de techniques (Document F). Ann Biol Clin (Paris) 1992 ; 50 : 727-30.
10. Di Serio F, Ruggieri V, Varraso L, De Sario R, Mastrorilli A, Pansini N. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005 ; 43 : 1263-73.
11. Yeo KTJ, Wu AHB, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003 ; 338 : 107-15.
12. Sokoll LJ, Baum H, Collinson PO, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004 ; 42 : 965-72.